DPP-4 inhibitor

Brigham and Women's Hospital · FDA-approved active Small molecule Quality 2/100

DPP-4 inhibitor is a Small molecule drug developed by Brigham and Women's Hospital. It is currently FDA-approved. Also known as: Sitagliptin, ALOGLIPTIN BENZOATE/METFORMIN HCL, ALOGLIPTIN BENZOATE, ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL.

DPP-4 inhibitors are a class of oral medications that block the enzyme dipeptidyl peptidase-4 (DPP-4) and are used to treat diabetes mellitus type 2. They are also being studied for other conditions, including diabetes, immune thrombocytopenia, blood coagulation disorders, and thrombocytopenia, although the specific indications may vary.

At a glance

Generic name	DPP-4 inhibitor
Also known as	Sitagliptin, ALOGLIPTIN BENZOATE/METFORMIN HCL, ALOGLIPTIN BENZOATE, ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL, SAXAGLIPTIN HCL
Sponsor	Brigham and Women's Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Effects of Cofrogliptin on Beta-Cell Function in LADA Patients (NA)
• A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy (PHASE4)
• Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
• Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus Patients
• Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis (PHASE4)
• Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC (PHASE4)
• Oral Anti Diabetic Agents in the Hospital (PHASE4)
• Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• DPP-4 inhibitor CI brief — competitive landscape report
• DPP-4 inhibitor updates RSS · CI watch RSS
• Brigham and Women's Hospital portfolio CI

Frequently asked questions about DPP-4 inhibitor

What is DPP-4 inhibitor?

DPP-4 inhibitor is a Small molecule drug developed by Brigham and Women's Hospital.

Who makes DPP-4 inhibitor?

DPP-4 inhibitor is developed and marketed by Brigham and Women's Hospital (see full Brigham and Women's Hospital pipeline at /company/brigham-and-women-s-hospital).

Is DPP-4 inhibitor also known as anything else?

DPP-4 inhibitor is also known as Sitagliptin, ALOGLIPTIN BENZOATE/METFORMIN HCL, ALOGLIPTIN BENZOATE, ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL, SAXAGLIPTIN HCL.

What development phase is DPP-4 inhibitor in?

DPP-4 inhibitor is FDA-approved (marketed).

Related

• Manufacturer: Brigham and Women's Hospital — full pipeline
• Also known as: Sitagliptin, ALOGLIPTIN BENZOATE/METFORMIN HCL, ALOGLIPTIN BENZOATE, ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL, SAXAGLIPTIN HCL